MGX סך נכסי הפעילות העסקית Metagenomi Inc.

International conflicts and sanctions hinder Metagenomi, Inc. (MGX) from accessing global genetic archives, slowing biomedical research. The absence of commercial products leaves the company dependent on external investments, with total assets amounting to 223.00. The market price reflected in this chart demonstrates the potential of this biotech firm, which is developing ultra-precise DNA modification tools based on unique microbial libraries for the therapy of complex pathologies.

Seeking to redefine gene editing precision standards through metagenomics, Metagenomi (MGX) requires significant resources to develop innovative CRISPR tools. An analysis of total assets, reverse-calculated via ROA and reaching a value of 223.00, allows for an assessment of the company's aggregate capital and liabilities, which for this class of venture securities serves as an indicator of financial stability and the scale of its technological potential.